Clinical trials: Bone Metastatic Castration-resistant Prostate Cancer
- Condition Bone Metastatic Castration-resistant Prostate Cancer
- Funder type Industry (pharma, biotech, devices)
Bone Metastatic Castration-resistant Prostate Cancer
A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones
In this study researcher want to gain more information on how the study drug (radium-223) is distributed in the bone, particularly in the tumor free bone in participants with prostate cancer.
- Trial name
- NCT04521361
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 12 sites in Austria, France and 4 more
- Volunteers
- 46 people
- Sponsor
- Bayer
Bone Metastatic Castration-resistant Prostate Cancer
A Study to Learn More About How Radium-223 is Being Used With Other Treatments in European Patients Who Have Not Received Radium-223 Before
In this study data from people with metastatic castration-resistant prostate cancer (mCRPC) with bone metastasis are studied. mCRPC is a prostate cancer which has spread to other parts of the body even when the amount of…
- Trial name
- DIRECT (NCT04587427)
- Testing
- Radium 223 dichloride (Xofigo, BAY88-8223)
- Where
- 3 sites in Denmark, Germany and 1 more
- Volunteers
- 1,067 people
- Sponsor
- Bayer
Metastatic Castration-Resistant Prostate Cancer
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
In this observational study researchers want to gather more information about bone fractures and survival in castration-resistant prostate cancer (CRPC) patients treated with radium-223 in routine clinical practice in Sweden.
- Trial name
- PRECISE (NCT04256993)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223), Other standard care
- Where
- Sweden
- Volunteers
- 1,434 people
- Sponsor
- Bayer
Metastatic Castration-resistant Prostate Cancer, Bone Metastases
A Research Called CREDIT Studies How Safe the Study Treatment Radium-223 is and How Well it Works in Chinese Men With Advanced Prostate Cancer That Has Spread to the Bones and Does Not Respond to Treatments for Lowering Testosterone Levels
This is an observational study in which data from Chinese men with metastatic castration-resistant prostate cancer that has spread to the bones and who start Radium-223 therapy is studied.
- Trial name
- CREDIT (NCT05301062)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Bayer
Bone-Metastatic, Castration-Resistant Prostate Cancer
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
The standard of care for patients with bone-metastatic, castrate-resistant prostate cancer is chemotherapy. If a patient elects not to choose chemotherapy, 70% will progress within 6 months.
- Trial name
- NCT01074138
- Testing
- KX2-391
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Athenex, Inc.
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer